

Jean Laurent Poitou, Chief Executive Officer

Dan Lévy, Chief Financial Officer

October 23rd, 2025





IPSOS HAS STRONG ASSETS TO ACCELERATE INTO ITS NEXT PHASE OF GROWTH

A UNIQUE POSITION AS INDEPENDENT LEADER IN MARKET RESEARCH

DIFFERENTIATED OFFERINGS ACCROSS ALL SECTORS

LEVERAGING BEST IN CLASS DATA AND METHODOLOGIES

LONG-TERM RELATIONSHIPS
WITH MAJOR PLAYERS FROM
ALL INDUSTRIES

GLOBAL REACH IN 90 MARKETS COMBINED WITH DEEP LOCAL KNOWLEDGE

HIGHLY-SKILLED PROFESSIONALS

SOUND FINANCIAL PROFILE



BUT WE CANNOT RELY ONLY ON WHAT GOT US HERE









CONVICTIONS THAT WILL GUIDE OUR DIRECTION

#1

A strong competitive advantage based on the historical richness of our data and panels

#2

A targeted and scalable use of Al, relying on these data, to accelerate our developments

#3

A resilient model based on our geographical reach, the wealth of our sectors and solutions, and the diversity of our expertises

INVEST WITH DISCIPLINE
AND WHERE RETURNS ARE DEMONSTRABLE



MY IMMEDIATE PRIORITIES

#1 **FINALIZE THE STRATEGY**

#2
STAY CLOSE TO THE FIELD

#3
RAISE THE BAR
ON EXECUTION





GOOD PERFORMANCE IN Q3 IN A COMPLEX ENVIRONMENT

9 MONTHS 2025

Q3

REVENUE	€ 1,791 м	€636м
Total Growth	+3.6%	+7.6%
Organic Growth	+0.7%	+2.9%
FX	-2.0%	-3.8%
Scope	4.9%	+8.5%



RETURN TO GROWTH IN THE U.S.

ORGANIC GROWTH

9 months

+0.9%

+3% organic growth since the beginning of 2025 excluding Public Affairs

Improvement in the Pharma sector

Good performance with CPG clients

The political context (DOGE, shutdown...) continues to impact

our Public Affairs business: -15% organic growth



GROWTH IMPROVEMENT ACROSS ALL REGIONS IN Q3

REVENUE GROWTH

In millions €	9 months 2025	Total	Organic	of which Q1	of which Q2	of which Q3
EMEA	872.8	10.0%	1.6%	-0.3%	1.8%	3.2%
Americas	630.3	-1.3%	1.2%	-1.7%	0.6%	4.3%
Asia-Pacific	287.9	-3.3%	-3.0%	-6.0%	-2.3%	-1.0%
Total	1,791.0	3.6%	0.7%	-1.8%	0.7%	2.9%



GOOD PERFORMANCE ACROSS MOST AUDIENCES, HELD BACK BY PUBLIC AFFAIRS BUSINESS

REVENUE GROWTH

In millions €	9 months 2025	Total	Organic	of which Q1	of which Q2	of which Q3
Consumers ¹	881.5	2.8%	2.0%	-0.6%	1.6%	4.9%
Clients & employees ²	360.0	3.5%	2.0%	0.5%	2.7%	2.9%
Citizens ³	285.3	5.1%	-9.2%	-14.2%	-8.7%	-4.7%
Doctors & patients ⁴	264.1	4.4%	5.0%	5.4%	5.2%	4.4%
Total	1,791.0	3.6%	0.7%	-1.8%	0.7%	2.9%

Breakdown of each Service Line by segment: breakdown of revenue by audience segment is non-financial data, likely to change over time depending on changes to the organization of Ipsos teams.

Excluding Public Affairs, organic growth for the first 9 months stands at 2.3%



^{1.} Brand Health Tracking, Creative Excellence, Innovation, Ipsos UU, Ipsos MMA, Market Strategy & Understanding, Observer (excl. public sector), Ipsos Synthesio, Strategy 3

^{2.} Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel Performance (including Mystery Shopping and Shopper), Media development, ERM, Capabilities

^{3.} Public Affairs, Corporate Reputation

^{4.} Pharma (quantitative and qualitative)


CONTINUED MOMENTUM ON IPSOS.DIGITAL

9 months 2025

GROWTH 28%

PROFITABILITY X2 vs Group profitability

2025 TARGET



© Ipsos | 2025 Third Quarter Results

OUTLOOK 2025 ORGANIC GROWTH OPERATING MARGIN ~13% ~0.7% at constant scope

THANK YOU

NEXT EVENTS

INVESTOR DAY 22.01.26

2025 ANNUAL RESULTS 25.02.26

Q&A SESSION

Dial-in phone numbers:

France: +33 170 91 87 04 UK: +44 121 281 8004 US: +1718 705 8796

Password: Ipsos

